These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
702 related articles for article (PubMed ID: 30983177)
1. [HELLP syndrome and hemolytic uremic syndrome during pregnancy: two disease entities, same causation. Case report and literature review]. Mancini A; Ardissino G; Angelini P; Giancaspro V; La Raia E; Nisi M; Proscia A; Tarantino G; Vitale O; D'elia F G Ital Nefrol; 2019 Apr; 36(2):. PubMed ID: 30983177 [TBL] [Abstract][Full Text] [Related]
2. Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS-Case Report. Lokki AI; Haapio M; Heikkinen-Eloranta J Front Immunol; 2020; 11():548. PubMed ID: 32308654 [TBL] [Abstract][Full Text] [Related]
3. Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report. Sevinc M; Basturk T; Sahutoglu T; Sakaci T; Koc Y; Ahbap E; Akgol C; Kara E; Brocklebank V; Goodship TH; Kavanagh D; Unsal A J Med Case Rep; 2015 Apr; 9():92. PubMed ID: 25925370 [TBL] [Abstract][Full Text] [Related]
4. A life-threatening case of pregnancy-related atypical Haemolytic uremic syndrome and successful treatment with Eculizumab. Puri P; Hanxhiu A; O'Hara DV; Hsu D; Vucak-Dzumhur M BMC Nephrol; 2020 Nov; 21(1):488. PubMed ID: 33203373 [TBL] [Abstract][Full Text] [Related]
5. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480 [TBL] [Abstract][Full Text] [Related]
6. Relapse of Atypical Hemolytic Uremic Syndrome During Pregnancy in a Patient on Eculizumab Maintenance Treatment: A Case Report. Fontana F; Alfano G; Bardhushi E; Ligabue G; Giovanella S; Neri I; Cappelli G Am J Case Rep; 2019 Oct; 20():1460-1465. PubMed ID: 31582717 [TBL] [Abstract][Full Text] [Related]
7. Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: A case report. Abe T; Sasaki A; Ueda T; Miyakawa Y; Ochiai H Medicine (Baltimore); 2017 Feb; 96(6):e6056. PubMed ID: 28178155 [TBL] [Abstract][Full Text] [Related]
8. Complement-Mediated Thrombotic Microangiopathy in Pregnancy: An Educational Case Report. Bruno V; Barth D; Jauhal A Can J Kidney Health Dis; 2023; 10():20543581231209009. PubMed ID: 37942411 [TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568 [TBL] [Abstract][Full Text] [Related]
10. The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring. Mannucci PM; Cugno M Thromb Res; 2015 Nov; 136(5):851-4. PubMed ID: 26386489 [TBL] [Abstract][Full Text] [Related]
11. Severe HELLP syndrome masquerading as thrombocytopenic thrombotic purpura: a case report. Mousseaux C; Joly BS; Mohamadou I; Arrestier R; Hertig A; Rafat C BMC Nephrol; 2020 May; 21(1):204. PubMed ID: 32471388 [TBL] [Abstract][Full Text] [Related]
12. Complement Activation and Thrombotic Microangiopathies. Palomo M; Blasco M; Molina P; Lozano M; Praga M; Torramade-Moix S; Martinez-Sanchez J; Cid J; Escolar G; Carreras E; Paules C; Crispi F; Quintana LF; Poch E; Rodas L; Goma E; Morelle J; Espinosa M; Morales E; Avila A; Cabello V; Ariceta G; Chocron S; Manrique J; Barros X; Martin N; Huerta A; Fraga-Rodriguez GM; Cao M; Martin M; Romera AM; Moreso F; Manonelles A; Gratacos E; Pereira A; Campistol JM; Diaz-Ricart M Clin J Am Soc Nephrol; 2019 Dec; 14(12):1719-1732. PubMed ID: 31694864 [TBL] [Abstract][Full Text] [Related]
13. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. Asif A; Nayer A; Haas CS J Nephrol; 2017 Jun; 30(3):347-362. PubMed ID: 27848226 [TBL] [Abstract][Full Text] [Related]
14. A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome/complement-mediated thrombotic microangiopathy. Che M; Moran SM; Smith RJ; Ren KYM; Smith GN; Shamseddin MK; Avila-Casado C; Garland JS Kidney Int; 2024 May; 105(5):960-970. PubMed ID: 38408703 [TBL] [Abstract][Full Text] [Related]
15. Eculizumab in secondary atypical haemolytic uraemic syndrome. Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M Nephrol Dial Transplant; 2017 Mar; 32(3):466-474. PubMed ID: 28339660 [TBL] [Abstract][Full Text] [Related]